President Trump has signed an executive order to ease restrictions on the psychedelic drug ibogaine, aiming to boost U.S. research into its potential medical benefits, particularly for treating post-traumatic stress disorder. Joined by Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, Trump announced a $50 million federal investment in ibogaine research. The order also allows ibogaine to be administered to critically ill patients under the FDA’s Right To Try rule, with a focus on helping veterans. FDA Commissioner Marty Makary stated that ibogaine and two other psychedelics would be added to a program to expedite drug review processes. Although ibogaine has shown promise in treating depression, anxiety, addiction, and PTSD, more extensive clinical trials are needed to confirm its safety and effectiveness. The federal government is still determining how to support further research, as ibogaine remains a Schedule I substance.
QUESTION: How might the increased research and potential use of ibogaine impact the treatment of mental health issues in the future?
Trump signs executive order to research psychedelics for mental health
